- Hansoh Pharma FY25 profit for the year climbed 27.1% to RMB 5.6 billion.
- Revenue rose 22.6% to RMB 15 billion.
- Basic earnings per share increased 26.4% to RMB 0.93.
- Innovative medicines and collaborative products revenue jumped 30.4% to RMB 12.4 billion, lifting mix to 82.2% of revenue.
- Board recommended final dividend of HK$0.20 per share; full-year dividend totaled HK$0.43 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on March 29, 2026, and is solely responsible for the information contained therein.
Comments